Split History
MRNS split history picture
Marinus Pharmaceuticals (MRNS) has 1 split in our MRNS split history database. The split for MRNS took place on September 23, 2020. This was a 1 for 4 reverse split, meaning for each 4 shares of MRNS owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 250 share position following the split.

When a company such as Marinus Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the MRNS split history from start to finish, an original position size of 1000 shares would have turned into 250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Marinus Pharmaceuticals shares, starting with a $10,000 purchase of MRNS, presented on a split-history-adjusted basis factoring in the complete MRNS split history. MRNS split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 08/01/2014
End date: 09/30/2022
Start price/share: $32.00
End price/share: $6.65
Dividends collected/share: $0.00
Total return: -79.22%
Average Annual Total Return: -17.49%
Starting investment: $10,000.00
Ending investment: $2,079.08
Years: 8.17
Marinus Pharmaceuticals is a pharmaceutical company focused on developing and commercializing products for patients suffering from rare genetic epilepsies and other seizure disorders. The U.S Food and Drug Administration approved the use of ZTALMY® (ganaxolone) oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder in patients two years of age and older. Ganaxolone is being developed in formulations for various routes of administration: intravenous and oral. Ganaxolone acts at both synaptic and extrasynaptic gamma-aminobutyric acid type A receptors, a target known for its anti-seizure, antidepressant and anxiolytic potential. According to our MRNS split history records, Marinus Pharmaceuticals has had 1 split.
Date Ratio
09/23/20201 for 4
MRNS is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

MSON Split History
MTEM Split History
MYG Split History
MYGN Split History
MYL Split History
MYMD Split History
MYO Split History
NATR Split History
NAVB Split History
NBS Split History

Also explore: MRNS shares outstanding history

Email EnvelopeFree MRNS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

American Virtual Cloud Technologies, Inc. (AVCT)
Avenue Therapeutics, Inc. (ATXI)
Annaly Capital Management, Inc. (NLY)
CohBar, Inc. (CWBR)
TOP Ships Inc. (TOPS)
Sonnet BioTherapeutics Holdings, Inc. (SONN)
Nabriva Therapeutics plc (NBRV)
NeuroBo Pharmaceuticals, Inc. (NRBO)
First Wave BioPharma, Inc. (FWBI)
Palatin Technologies, Inc. (PTIN)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

MRNS Insider Buying

MRNS Split History | www.SplitHistory.com | Copyright © 2013 - 2022, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.